Urology’s prior-authorization burden runs across two distinct patient populations. For benign urological conditions — particularly overactive bladder — step therapy requirements force patients through agents with well-characterized side-effect burdens before reaching the drugs that work better. For oncologic urology — prostate cancer, bladder cancer, renal cell carcinoma — high-cost drugs require prior authorization with criteria that don’t always track clinical guidelines.
The patients are different. The mechanism is the same: documentation overhead standing between the clinician’s decision and the patient’s treatment.
The numbers in urology
Urology-specific PA data is limited in the peer-reviewed literature, but the AMA’s 2024 Prior Authorization Physician Survey captures the cross-specialty burden:
- 82% of physicians say PA can lead patients to abandon treatment.
- 93% say PA delays patient care.
- 29% report PA led to a serious adverse event.
- 39 authorizations per physician per week, ~13 hours lost to them (AMA 2024).
In urology, treatment abandonment has specific meaning. An OAB patient who stops pursuing treatment after being required to document oxybutynin failure isn’t just inconvenienced — they’re living with a condition that significantly affects quality of life. A prostate cancer patient who can’t get abiraterone authorized has real oncologic consequences.
Why urology is different
- OAB step therapy through an anticholinergic. The standard payer pathway for overactive bladder medication requires documented failure of oxybutynin before approving mirabegron or vibegron. Oxybutynin has well-documented anticholinergic side effects — including cognitive effects relevant in elderly patients. Urologists who want to prescribe a better-tolerated agent for an older patient are required to document why oxybutynin isn’t appropriate, not simply prescribe mirabegron.
- Oncologic drug sequencing criteria. Enzalutamide, abiraterone, darolutamide, and other advanced prostate cancer drugs each require PA with payer-specific criteria for disease stage, PSA levels, and prior therapy. As the treatment landscape has expanded to include combination regimens and sequencing approaches, the documentation requirements have grown more complex.
- Testosterone therapy gating. Testosterone replacement therapy requires PA from most payers, with documentation of two low serum testosterone levels, symptoms, and often a workup for secondary causes — creating an authorization loop for a straightforward clinical scenario.
- Surgical procedure PA. Procedures including sacral neuromodulation for OAB, penile prostheses, and urological cancer resections require PA, often with conservative management documentation requirements that parallel orthopedic and pain management patterns.
What it costs
The OAB cost is quality of life delayed: patients who genuinely benefit from mirabegron or vibegron spending weeks on a medication they’ll discontinue due to side effects, all to satisfy a step-therapy requirement that precedes the real clinical conversation. The oncologic cost is more acute — delays in prostate cancer drug authorization represent time the disease may be progressing. The operational cost is per-patient documentation across two very different patient populations, at roughly $10.81 per manually processed authorization (CAQH 2023), with different documentation requirements for each drug class.
How to cut the wait
Urology’s PA documentation is patient-specific clinical history: OAB patients need prior medication records and side-effect documentation; prostate cancer patients need PSA history, staging, and prior therapy records. Artificer Health:
- Builds the step-therapy record — prior medications, duration, outcomes, and the anticholinergic-intolerance or side-effect documentation that justifies bypassing the formulary default.
- Assembles oncologic documentation — PSA history, disease staging, prior treatment records, and the payer-specific criteria each advanced prostate cancer drug requires.
- Tracks re-authorizations for ongoing hormone therapy and maintenance treatment so coverage doesn’t lapse during active disease management.
For the OAB patient, it’s a faster path to the medication that actually works. For the prostate cancer patient, it’s treatment that starts this week instead of next month.
Sources: AMA 2024 Prior Authorization Physician Survey (n=1,000); payer medical policies for overactive bladder (oxybutynin step therapy), testosterone replacement, and advanced prostate cancer drugs (enzalutamide, abiraterone); CAQH 2023 Index.